# Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis

> **NCT01807286** · PHASE1 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 3 (actual)

## Conditions studied

- Myeloma

## Interventions

- **DRUG:** Pomalidomide
- **DRUG:** Melphalan
- **DRUG:** Dexamethasone
- **BEHAVIORAL:** Questionnaires

## Key facts

- **NCT ID:** NCT01807286
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-01
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Sponsor requested termination
- **Last updated:** 2016-05-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01807286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01807286, "Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01807286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*